Samer Renno, MD
Hematology & Oncology · Omaha, NENPI 1588758312
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,158 of the $41,380 with a category attached, or 68.0%. 30 manufacturers reported payments, led by AstraZeneca at 35.1% of the total. Reporting peaked in 2019 at $31,200 and has fallen 97.5% since, to $774 in 2025.
Across 149 payments — averaging $277.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Amgen$7K
- Seagen Inc.$6K
- AbbVie$5K
- Tesaro, Inc.$4K
- Johnson & Johnson$1K
- plus $3K from 24 others
What the payments were for
- Consulting fees$28,15868%
- Speaking & faculty fees$5,12512%
- Travel & lodging$4,89212%
- Food & beverage$2,8397%
- Education$3661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 22 | $14,538 |
| Amgen | 9 | $7,045 |
| Seagen Inc. | 12 | $6,259 |
| AbbVie | 19 | $4,749 |
| Tesaro, Inc. | 10 | $4,346 |
| Johnson & Johnson | 6 | $1,354 |
| Daiichi Sankyo Inc. | 7 | $1,061 |
| Mckesson Specialty Care Distribution, LLC | 1 | $670 |
| E.r. Squibb & Sons, L.L.C. | 16 | $232 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $138 |
| Iovance Biotherapeutics, Inc. | 1 | $123 |
| Merck | 6 | $99 |
| Eisai Inc. | 4 | $82 |
| Incyte Corporation | 1 | $82 |
| Novartis | 4 | $73 |
| Astellas Pharma US Inc | 3 | $71 |
| Genentech USA, Inc. | 3 | $66 |
| Acrotech Biopharma Inc. | 5 | $66 |
| Pharmaessentia USA Corporation | 3 | $62 |
| Pfizer | 3 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Beone Medicines USA, Inc. | 1 | $34 |
| Octapharma USA, Inc. | 1 | $25 |
| Geron Corporation | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,380 in reported general payments places this provider in the 85th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 31 | $501,042 |
| JakafiRuxolitinib Phosphate | 23 | $370,936 |
| Lenalidomide | 31 | $339,570 |
| ZejulaNiraparib Tosylate | 11 | $296,925 |
| VenclextaVenetoclax | 31 | $264,391 |
| BrukinsaZanubrutinib | 16 | $202,127 |
| CalquenceAcalabrutinib Maleate | 12 | $163,099 |
| EliquisApixaban | 65 | $41,290 |
| XareltoRivaroxaban | 30 | $23,201 |
| Abiraterone Acetate | 54 | $20,216 |
| Anastrozole | 282 | $4,601 |
| Tamoxifen Citrate | 122 | $3,245 |
| Diphenhydramine Hcl | 14 | $1,841 |
| Hydroxyurea | 89 | $1,685 |
| Anagrelide Hcl | 15 | $1,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $138 | $501,04231 claims |
| Incyte CorporationJakafi | $82 | $370,93623 claims |
| GSKZejula | $18 | $296,92511 claims |
| AbbVieVenclexta | $4,749 | $264,39131 claims |
| AstraZenecaCalquence | $14,538 | $163,09912 claims |
| PfizerEliquis | $46 | $41,29065 claims |
| Johnson & JohnsonXarelto | $1,354 | $23,20130 claims |
| Lilly USA, LLCOlanzapine | $21 | $46833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
- Marcel DevettenOmaha$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.